Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
14.81
-0.55 (-3.58%)
At close: Aug 19, 2022 4:00 PM
15.16
+0.35 (2.36%)
After-hours:
Aug 19, 2022 4:21 PM EDT
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue
|
38.49 | 0 | 0 | 0 |
| Gross Profit
|
38.49 | 0 | 0 | 0 |
| Selling, General & Admin
|
74.11 | 65.26 | 57.47 | 40.98 |
| Research & Development
|
220.18 | 192.99 | 144.54 | 151.86 |
| Operating Expenses
|
294.28 | 258.24 | 202.01 | 192.84 |
| Operating Income
|
-255.79 | -258.24 | -202.01 | -192.84 |
| Interest Expense / Income
|
0 | 0 | 0 | 3.36 |
| Other Expense / Income
|
1.21 | -8.02 | -17.08 | 15.42 |
| Pretax Income
|
-257.01 | -250.22 | -184.93 | -211.62 |
| Income Tax
|
0 | 0 | -0.33 | -0.12 |
| Net Income
|
-257.01 | -250.22 | -184.59 | -211.51 |
| Net Income Common
|
-257.01 | -250.22 | -184.59 | -211.51 |
| Shares Outstanding (Basic)
|
136 | 120 | 101 | 29 |
| Shares Outstanding (Diluted)
|
136 | 120 | 101 | 29 |
| Shares Change
|
12.84% | 19.11% | 249.11% | - |
| EPS (Basic)
|
-1.89 | -2.08 | -1.83 | -7.31 |
| EPS (Diluted)
|
-1.89 | -2.08 | -1.83 | -7.31 |
| Free Cash Flow Per Share
|
-1.52 | -1.50 | -1.86 | -1.65 |
| Gross Margin
|
100.00% | - | - | - |
| Operating Margin
|
-664.60% | - | - | - |
| Profit Margin
|
-667.70% | - | - | - |
| Free Cash Flow Margin
|
-535.90% | - | - | - |
| Effective Tax Rate
|
0.00% | 0.00% | 0.18% | 0.06% |
| EBITDA
|
-246.55 | -242.79 | -180.5 | -207.22 |
| EBITDA Margin
|
-640.60% | - | - | - |
| Depreciation & Amortization
|
10.45 | 7.44 | 4.42 | 1.05 |
| EBIT
|
-257.01 | -250.22 | -184.93 | -208.26 |
| EBIT Margin
|
-667.70% | - | - | - |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).